Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-01-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于更换持续督导保荐代表人的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a specific private placement stock issuance project by Shenzhen BGI Genomics Co., Ltd. It details the replacement of a sponsor representative due to job changes and confirms the continuity of supervision work. The document does not contain financial statements, earnings data, or detailed report content. It is a regulatory announcement about management of a financing project rather than a full report or financial disclosure. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to ongoing supervision of a capital raising project.
2024-01-25 Chinese
关于开展外汇套期保值业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the continuation of foreign exchange hedging business for the year 2024. It details the purpose, transaction methods, amounts, risk analysis, internal approvals, and regulatory compliance related to the hedging activities. The document includes board and supervisory committee meeting approvals and independent director opinions. It is a formal disclosure about the company's hedging strategy and risk management but does not contain financial statements or detailed financial results. It is not an earnings release, annual or interim report, or audit report. It is also not a call transcript, M&A, or capital financing update. The document is a regulatory announcement about a specific financial risk management activity, consistent with a Regulatory Filings (RNS) classification, which is the fallback for miscellaneous regulatory disclosures that do not fit other categories. The document length is about 5472 characters, which is substantive and not a mere brief notice or report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-01-19 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a specific board meeting of Shenzhen BGI Genomics Co., Ltd. It details the convening of the board meeting, the agenda items discussed, voting results, and references to related announcements and approvals. The content focuses on board decisions regarding daily related-party transactions, cash management, foreign exchange hedging, and the scheduling of a shareholders' meeting. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full annual or interim report, nor is it a call transcript or audit report. It is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 3097 characters, which is typical for such announcements and not a full report. Therefore, the correct classification is MANG with high confidence.
2024-01-19 Chinese
关于使用暂时闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the use of temporarily idle own funds for cash management. It details the investment purpose, types, amounts, risks, and approvals by the board and supervisory committee. The document is a formal disclosure about financing activities related to cash management and investment of idle funds, not a financial report or earnings release. It does not contain financial statements or detailed financial results but rather an update on capital usage and risk control measures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 4710 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2024-01-19 Chinese
关于2024年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the expected daily related party transactions for the year 2024 and the actual related party transactions for 2023. It includes extensive tables of transaction categories, amounts, related parties, and explanations of approval procedures and compliance with regulatory rules. The document is not a financial report like an annual or quarterly report, nor is it a call transcript or earnings release. It is a regulatory announcement about related party transactions, which is a common disclosure for listed companies to comply with stock exchange rules. The document is lengthy (15,000 characters) and contains substantive data about related party transactions, approvals, and compliance, but it is not a financial statement or management discussion. It fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about related party transactions and compliance disclosures that do not fit other specific categories.
2024-01-19 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2024年度日常关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the anticipated and actual related party transactions for Shenzhen BGI Genomics Co., Ltd. for the year 2024 and the actual transactions for 2023. It includes extensive financial data, transaction categories, amounts, approval processes, and related party descriptions. The content focuses on the company's related party transactions, their approval, and compliance with regulatory requirements. This is not a brief announcement or a certification letter but a substantive report with detailed financial and operational data about related party transactions. Such detailed disclosure and analysis of related party transactions typically fall under the category of Regulatory Filings (RNS) because it is a regulatory disclosure about related party transactions rather than a financial report like an Annual Report or Interim Report. It is not an announcement of voting results, management changes, or other categories. Therefore, the best fit is Regulatory Filings (RNS).
2024-01-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.